News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News NICE approval for Keytruda a 'milestone' in lung cancer But drug will not be funded for longer than two years.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News BMS and Infinity look to boost Opdivo in lung cancer Companies look for combinations in lung cancer and other tumours.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
